Associazione Nazionale Medici Cardiologi Ospedalieri

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
24-HOUR PULMONARY ARTERY ELASTANCE IS THE STRONGEST HEMODYNAMIC PREDICTOR OF IN-HOSPITAL MORTALITY IN ACUTE DECOMPENSATED HEART FAILURE-RELATED CARDIOGENIC SHOCK
Anno:
2023
Aim     The initial bundle of cares strongly affects hemodynamics in acute decompensated heart failure cardiogenic shock (ADHF-CS). We sought to characterize whether 24-hour hemodynamic profiling provides superior prognostic information as compared to admission assessment, and which hemodynamic parameters best predict in-hospital death.   Methods and results We included 99…
TEMPORAL TREND MORTALITY AND IN-HOSPITAL MORTALITY PREDICTORS IN AN ISCHEMIC CARDIOGENIC SHOCK POPULATION: A 10 YEARS SINGLE-CENTRE RETROSPECTIVE STUDY
Anno:
2023
Background Cardiogenic shock (CS) after acute myocardial infarction (AMI) represents the most severe form of acute heart failure (AHF) syndromes with an high rate of in-hospital mortality. Purpose describe predictors of in-hospital mortality; evaluate ten years mortality temporal trend in our CICU; assess the feasibility of CARDSHOCK risk score;…
Lights and shadows of the microcoaxial pump device in a unique setting: cardiogenic shock due to acute myocardial infarction in patient with unknown hypertrophic cardiomyopathy
Anno:
2023
Cardiogenic shock remains the leading cause of death in patients with acute myocardial infarction (AMICS). The IntraAortic Balloon Pump (IABP) has been the device of first choice for these patients for years, but it has not shown a mortality benefit over optimal medical therapy. The Impella (AbioMed, Danvers, Massachusetts) is…
EFFICACY AND SAFETY OF LEVOSIMENDAN IN AN ISCHEMIC CARDIOGENIC SHOCK POPULATION: A 10-YEARS SINGLE CENTRE RETROSPECTIVE STUDY
Anno:
2023
Background: Levosimendan is a Ca²⁺-sensitizer with inodilator action able to improve cardiac contractility without increse oxygen demand. In AHF setting clinical trial and registries showed an improvement in systemic haemodynamics without a decrease in in-hospital mortality. Purpose: evaluate safety and efficacy of Levosimendan in an ischemic CS population. Methods:…
PROCALCITONIN AS PREDICTOR OF IN-HOSPITAL MORTALITY IN A CARDIOGENIC SHOCK POPULATION: A 10-YEARS SINGLE CENTRE RETROSPECTIVE STUDY
Anno:
2023
Background: Plasmatic procalcitonin (PCT) is an acute-phase inflammatory marker, its value tends to increase during inflammatory conditions such as septic shock, cardiogenic shock (CS) and bacterial infections. Patients with CS complicating acute myocardial infarction (AMI) and signs of systemic inflammatory response syndrome (SIRS) can show increased PCT values but its…
PREVALENCE CHARACTERISTICS AND OUTCOMES OF COVID 19 ASSOCIATED ACUTE MYOCARDITIS
Anno:
2023
BACKGROUND: Acute myocarditis (AM) is thought to be a rare cardiovascular complication of COVID-19, although minimal data are available beyond case reports. We aim to report the prevalence, baseline characteristics, in-hospital management, and outcomes for patients with COVID-19–associated AM on the basis of a retrospective cohort from 23 hospitals…